Niagen Bioscience Inc (NAGE) Stock Price, Quote & News

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 388 6706

Website: www.niagenbioscience.com

Address:

10900 Wilshire Blvd, Suite 600, Los Angeles, United States

wycliff Aug. 4 at 3:49 AM

$NAGE https://www.aboutnad.com/pages/what-is-nicotinamide-riboside

0 · Reply

wycliff Aug. 4 at 3:49 AM

$NAGE https://clinicaltrials.gov/study/NCT07741071

0 · Reply

wycliff Aug. 4 at 2:59 AM

$NAGE https://cdn.shopify.com/s/files/1/0705/7024/6332/files/External_StateOfTheScience_V8.2.pdf?v=1760061604

0 · Reply

wycliff Aug. 4 at 2:29 AM

$NAGE https://insight.jci.org/articles/view/203826

0 · Reply

wycliff Aug. 4 at 1:29 AM

$NAGE https://www.aboutnad.com/blogs/blog/what-is-inflammaging-the-role-of-nad-in-chronic-inflammation-and-aging

0 · Reply

wycliff Aug. 3 at 7:32 PM

$NAGE https://x.com/niagenbio/status/2084361207545262473?s=10

0 · Reply

wycliff Aug. 3 at 5:16 PM

$NAGE https://x.com/longevitytech/status/2084283124473598137?s=10

0 · Reply

Impalas283 Aug. 3 at 1:55 PM

$NAGE How many years will it take for the pharmaceutical efforts to pay off?

1 · Reply

focafoca99 Aug. 3 at 12:53 PM

$NAGE collaborates with Evotec to advance preclinical development of NB4168 for Ataxia Telangiectasia.

0 · Reply

wycliff Aug. 3 at 12:39 PM

$NAGE https://u11022783.ct.sendgrid.net/ls/click?upn=u001.yE7s-2BLdkb6CTaqFVaPuvDCGn2arZv6qxs-2B6yVMiuS4A0Ke0MPS4v7u0pP1iL-2BZ1VW5HcMP4PmA4PEdEc6WPsHf7OffS-2B1v51MJH-2FYunq-2BD39YaLbVECSiKp4ZHCb6RX8gaygGLpc4wr-2FP1kFTgIVaXdgXnLMPlG4LIY0zEa9lSeb0pOFM6MQDGT83ZIWCRKNByYPBQ-2B-2FbPIg6PrbqTw3C1uhRpKLqZHShibYYLwhYhEo9N3C13h7-2FjpQjaSnX1zQnFQeaFECBkSK0aQW-2FPYL7w-3D-3D1g9C_yi-2FF8O9dI2IZIjwMOLdjRPz-2FbuGWjWoi1PmCLi4JX8FeCZ-2FDiYZltXM3qUuENtbaP26Or7P6OUmFJt1NBMkhjdDvM0rrAWK-2BfbMWfLrkyj4P24gmn1xR3cxcPCHP74YbnyrgV4INQZ5iHgZ-2FFfZkyC49EbSI9RCuz6ft0aRTkbDTJh9LLxe3hV2kXbNKvczJdHI3c-2FQ1exwwegFd7PTRcZlorWxMGD-2F0MYtC2gqKEEo5jo7nkMtydWqBglLMmdW1KUErYQtcrgiWJyLLthzauq-2B6rh1UkZKMp2oT7gv2-2FnFore7FAiIWfQ5LuJZSDbq2SYTm1A9rVhKFR6btIKBEwkz63IdemFJwzWHAPb5g-2Fw8U8WP10bhCc6v0ag7i4UjOLaETR7nhVTozhdEvfAru44h-2BP5NZP7ffQ0h5GLnBdD3EpLh5K2wiz4hy2bzNIIb6

0 · Reply

Niagen Bioscience selects Evotec to advance development for NB4168

EVO

Aug 3, 2026, 8:32 AM EDT - 17 hours ago

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

EVO

2026-07-28T12:41:24.000Z - 6 days ago

Niagen Bioscience announces publication on muscle epigenetic age

Jul 28, 2026, 8:32 AM EDT - 6 days ago

Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging

Jul 27, 2026, 8:32 AM EDT - 7 days ago

Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference

Jul 21, 2026, 8:32 AM EDT - 13 days ago

Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

2026-07-21T12:00:36.000Z - 13 days ago

Niagen Bioscience price target lowered to $11 from $12 at Ladenburg

2026-07-16T12:46:33.000Z - 18 days ago

Niagen Bioscience appoints Kale as Senior Director of Global External Research

Jul 16, 2026, 8:32 AM EDT - 18 days ago

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Jul 15, 2026, 11:00 AM EDT - 19 days ago

Niagen Bioscience Transcript: Fireside chat

Jul 15, 2026, 7:00 AM EDT - 19 days ago

Niagen Bioscience Slides: Corporate presentation

2026-07-13T12:35:07.000Z - 21 days ago

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Jul 13, 2026, 8:32 AM EDT - 21 days ago

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Jul 9, 2026, 8:32 AM EDT - 25 days ago

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

2026-07-08T12:40:25.000Z - 26 days ago

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Jul 8, 2026, 8:32 AM EDT - 26 days ago

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

2026-07-06T19:10:21.000Z - 4 weeks ago

Niagen Bioscience initiated with a Buy at Freedom Broker

Jun 29, 2026, 8:00 AM EDT - 5 weeks ago

Niagen Bioscience Registration statement: Registration filing

2026-06-29T10:25:42.000Z - 5 weeks ago

Niagen Bioscience files $125M mixed securities shelf

Jun 11, 2026, 2:40 PM EDT - 7 weeks ago

Niagen Bioscience Transcript: 16th Annual East Coast IDEAS Conference

Jun 3, 2026, 8:34 AM EDT - 2 months ago

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

2026-06-02T15:25:33.000Z - 2 months ago

Niagen Bioscience renames CERP to Niagen Research Program

Jun 2, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

2026-05-11T10:46:50.000Z - 3 months ago

Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright

May 8, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

2026-05-07T20:07:38.000Z - 3 months ago

Niagen Bioscience price target lowered to $12 from $13 at Roth Capital

2026-05-07T01:51:30.000Z - 3 months ago

Niagen Bioscience reports Q1 EPS 7c, consensus 6c

2026-05-07T01:50:48.000Z - 3 months ago

Niagen Bioscience sees 2026 sales growth 10%-15%

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Slides: Q1 2026

May 6, 2026, 4:02 PM EDT - 3 months ago

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

May 6, 2026, 7:00 AM EDT - 3 months ago

Niagen Bioscience Slides: Corporate presentation

2026-05-05T11:04:12.000Z - 3 months ago

Niagen Bioscience price target lowered to $10 from $13 at Canaccord

2026-05-04T13:07:08.000Z - 3 months ago

Niagen Bioscience launches Niagen Plus telehealth plarform

May 4, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Niagen Bioscience Proxy statement: Proxy filing

2026-04-28T12:57:11.000Z - 3 months ago

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

2026-04-28T12:51:55.000Z - 3 months ago

Niagen Bioscience announces new partnership with Olympia Pharmaceuticals

Apr 28, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Apr 22, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

2026-04-09T14:14:54.000Z - 4 months ago

Niagen Bioscience collaborates with USP to establish USP monograph

Apr 9, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

2026-03-31T13:06:28.000Z - 4 months ago

Niagen announces first cruise ship clinic partnership with OneSpaWorld

OSW

Mar 31, 2026, 8:34 AM EDT - 4 months ago

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

OSW

2026-03-19T12:50:32.000Z - 4 months ago

Niagen Bioscience increases share repurchase program to $20M

Mar 19, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Mar 18, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Mar 17, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Mar 10, 2026, 8:32 AM EDT - 5 months ago

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Slides: Q4 2025

Mar 4, 2026, 4:02 PM EST - 5 months ago

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Mar 4, 2026, 7:00 AM EST - 5 months ago

Niagen Bioscience Slides: Corporate presentation

Feb 26, 2026, 7:02 AM EST - 5 months ago

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Feb 25, 2026, 8:32 AM EST - 5 months ago

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Feb 9, 2026, 8:34 AM EST - 6 months ago

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Feb 6, 2026, 8:32 AM EST - 6 months ago

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Jan 15, 2026, 11:30 AM EST - 7 months ago

Niagen Bioscience Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 8:34 AM EST - 7 months ago

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Dec 22, 2025, 8:32 AM EST - 8 months ago

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Nov 13, 2025, 8:32 AM EST - 9 months ago

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Nov 12, 2025, 7:52 PM EST - 9 months ago

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Nov 6, 2025, 8:07 AM EST - 9 months ago

Niagen Bioscience Announces $10 Million Share Repurchase Program

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 9 months ago

Niagen Bioscience Slides: Q3 2025

Nov 4, 2025, 4:02 PM EST - 9 months ago

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Nov 4, 2025, 7:00 AM EST - 9 months ago

Niagen Bioscience Slides: Investor presentation

Oct 21, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 6, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Oct 1, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Sep 16, 2025, 8:32 AM EDT - 11 months ago

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Aug 12, 2025, 12:00 PM EDT - 1 year ago

Niagen Bioscience Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q2 2025

Aug 6, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Jul 23, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 14, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 8, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jun 20, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 11, 2025, 8:31 AM EDT - 1 year ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 9, 2025, 2:15 PM EDT - 1 year ago

Niagen Bioscience Transcript: 25th Annual Consumer Growth and E-Commerce Conference

Jun 9, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

May 9, 2025, 7:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q1 2025

May 7, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 5, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Apr 29, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Niagen Bioscience Proxy statement: Proxy Filing

Apr 28, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 7, 2025, 10:32 PM EDT - 1 year ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

wycliff Aug. 4 at 3:49 AM

$NAGE https://www.aboutnad.com/pages/what-is-nicotinamide-riboside

0 · Reply

wycliff Aug. 4 at 3:49 AM

$NAGE https://clinicaltrials.gov/study/NCT07741071

0 · Reply

wycliff Aug. 4 at 2:59 AM

$NAGE https://cdn.shopify.com/s/files/1/0705/7024/6332/files/External_StateOfTheScience_V8.2.pdf?v=1760061604

0 · Reply

wycliff Aug. 4 at 2:29 AM

$NAGE https://insight.jci.org/articles/view/203826

0 · Reply

wycliff Aug. 4 at 1:29 AM

$NAGE https://www.aboutnad.com/blogs/blog/what-is-inflammaging-the-role-of-nad-in-chronic-inflammation-and-aging

0 · Reply

wycliff Aug. 3 at 7:32 PM

$NAGE https://x.com/niagenbio/status/2084361207545262473?s=10

0 · Reply

wycliff Aug. 3 at 5:16 PM

$NAGE https://x.com/longevitytech/status/2084283124473598137?s=10

0 · Reply

Impalas283 Aug. 3 at 1:55 PM

$NAGE How many years will it take for the pharmaceutical efforts to pay off?

1 · Reply

focafoca99 Aug. 3 at 12:53 PM

$NAGE collaborates with Evotec to advance preclinical development of NB4168 for Ataxia Telangiectasia.

0 · Reply

wycliff Aug. 3 at 12:39 PM

0 · Reply

wycliff Aug. 2 at 6:58 AM

$NAGE https://share.gemini.google/Q1NZslJJG43O

0 · Reply

wycliff Aug. 2 at 6:54 AM

$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/qXkDQbXEn2

0 · Reply

wycliff Aug. 2 at 6:45 AM

$NAGE https://finance.yahoo.com/community/post/1b83e174-f2e8-4904-89f5-91abe9a2c120

0 · Reply

MattManzanita Aug. 2 at 3:50 AM

$NAGE Abstract Thu078: Targeting Oxidative Stress Via NAD+ Modulation to Mitigate Microvascular Disease A Kaw, T Yu, L Hansen - Arteriosclerosis, Thrombosis, and Vascular Biology, 2026 … This research investigates whether nicotinamide riboside (NR), vitamin B3 analogue and NAD + precursor that activates SIRT3, can reduce oxidative stress to restore endothelial homeostasis and prevent MVD progression. SIRT3 activation … [HTML] NAD and Glutathione: The Power-and-Protection Pair WNAD Is … Your body makes NAD from precursors, including a form of vitamin B3 called nicotinamide riboside, or NR. That precursor relationship is why most NAD supplements do not contain NAD itself, but rather the building blocks your cells use to make more of it. … Abstract Or123: Metabolic changes influence vascular smooth muscle cell differentiation state J Esparza Pinelo, AM Robin, A Dosunmu, A Richard… - … , Thrombosis, and Vascular …, 2026 …

0 · Reply

MattManzanita Aug. 2 at 3:24 AM

$NAGE 0965 Dihydronicotinamide riboside (NRH): A potent NAD+ booster for skin longevity MC Thorne1 , A Fahim1 , C Ruiz de Souza1 , C Rome1 , D Layman2 , J Chwee1 and C O’Connor1 1 DECIEM Beauty Group Inc, Toronto, Ontario, Canada and 2 Research and Development, The Este´e Lauder Companies, Melville, New York, United States Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor for generating cellular energy and maintaining skin homeostasis. NAD+ levels have been demonstrated to decline with age, leading to cellular aging that compromises the skin’s capacity for repair and renewal, ultimately contributing to the visible signs of aging. Consequently, there is great interest in developing ingredients that can boost cellular NAD+ concentrations for use in topical products that help promote skin health and slow the visible aspects of the aging trajectory. (continued)

2 · Reply

wycliff Aug. 1 at 11:17 PM

$NAGE https://www.ahajournals.org/doi/10.1161/atvb.46.suppl_1.Thu078

0 · Reply

okeydokey_artichokey Aug. 1 at 11:12 PM

$NAGE Welp, color me an increasing shade of positivity. Dihydronicotinamide riboside (NRH): A potent NAD+ booster for skin longevity MC Thorne1, A Fahim1, C Ruiz de Souza1, C Rome1, D Layman2, J Chwee1 and C O’Connor1 1 DECIEM Beauty Group Inc, Toronto, Ontario, Canada and 2 Research and Development, The Este ́e Lauder Companies, Melville, New York, United States "Overall, our findings establish NRH as a promising agent for enhancing NAD+ levels in skin cells, supporting its relevance in skin longevity research and potential incorporation into skincare formulations aimed at enhancing skin longevity, improving visible signs of aging, and supporting youthful skin." https://www.jidonline.org/article/S0022-202X(26)02277-3/pdf

1 · Reply

wycliff Aug. 1 at 2:53 PM

$NAGE https://www.linkedin.com/posts/therealjencohen_everyone-wants-the-next-anti-aging-shortcut-ugcPost-7487909152598425601-Qbuw?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA

0 · Reply

MattManzanita Aug. 1 at 1:03 AM

$NAGE Speculation, but AI is smater than me: what might estee lauder pay to license niagen in a skin care product AI: An exclusive global licensing agreement between a cosmetics giant like The Estée Lauder Companies and an ingredient innovator like Niagen Bioscience (formerly ChromaDex) would likely cost Estée Lauder $2 million to $10 million in upfront fees, plus a 3% to 7% running royalty rate on net product sales.Because Niagen holds powerful composition-of-matter patents and extensive clinical research backing its NAD+-boosting capabilities, it commands a premium in the "clinical" and prestige skincare sectors.A hypothetical deal structure would likely break down across the following industry benchmarks:1. Upfront Licensing & Exclusivity FeesTo secure the rights to market a prestige skincare line featuring Niagen—and crucially, to block competitors like L'Oréal from using it—Estée Lauder would pay a lump sum at signing.Prestige Beauty Benchmark: CONTINUED

5 · Reply

wycliff Jul. 31 at 5:46 AM

$NAGE https://www.linkedin.com/posts/no-age-ad-norway-242487421_big-congratulations-to-no-agead-advisor-share-7488656894572572672-ykid/?utm_source=share&utm_medium=member_ios&rcm=ACoAAAUGerIBOiyuZoO-6U9HRKRzZ48AD8YnjZA

1 · Reply

MattManzanita Jul. 30 at 5:10 PM

$NAGE Regarding BlackRock and other institutional owners incresing their NAGE shares: AI Overview Having a limited number of shortable shares helps a corporation by reducing stock price volatility, lowering the risk of coordinated downward pressure, and discouraging aggressive bearish speculation. Yahoo Finance +1 Key protective factors for the corporation include: Reduced Volatility: Fewer shares available to borrow and sell short prevent sharp, artificial drops in share price caused by sudden selling pressure. Street Of Walls +1 Deterring Bear Raids: High borrow fees ("hard-to-borrow" costs) make shorting expensive, discouraging speculators from aggressively betting against the company. U.S. News - Money Short Squeeze Protection: A constrained supply of shortable shares increases the risk for short sellers if positive news hits, often triggering a rapid price recovery as shorts rush to buy back shares. Yahoo Finance +1

0 · Reply

wycliff Jul. 29 at 10:50 PM

$NAGE https://share.gemini.google/QopCYC1IXm62

0 · Reply

Market Cap	270.79M
Revenue (ttm)	129.42M
Net Income (ttm)	17.38M
EPS (ttm)	N/A
PE Ratio	17.47
Forward PE	15.56
Profit Margin	13.43%
Debt to Equity Ratio	0.00

Volume	1,263,800
Avg Vol	766,144
Day's Range	N/A - N/A
Shares Out	79.64M
Stochastic %K	89%
Beta	2.09
Analysts	Strong Sell
Price Target	$10.60